Phase 2a randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of londamocitinib (AZD4604) two times per day for 12 weeks in adult patients with moderate-to-severe ast
4 days ago
- #JAK1 inhibitor
- #asthma
- #clinical trial
- Phase 2a randomised, double-blind, placebo-controlled study evaluating londamocitinib (AZD4604) in adults with moderate-to-severe asthma uncontrolled on medium-high-dose ICS-LABA.
- Primary endpoint: Time to first CompEx Asthma event.
- Secondary endpoints include changes in lung function, asthma control, and symptoms.
- Assessment of airway inflammation via fractional exhaled nitric oxide test and cough severity.
- Pharmacokinetics of londamocitinib evaluated at weeks 4 and 12.
- Ethical approval obtained, with findings to be disseminated through peer-reviewed publications and presentations.
- Study involves AstraZeneca employees and investigators with various competing interests.